Ab­b­Vie and Roche tout a pos­i­tive PhI­II com­bo study of Ven­clex­ta, Rit­ux­an in CLL — ahead of FDA pitch

Ab­b­Vie and Roche are get­ting a boost out of the news that their com­bi­na­tion of Ven­clex­ta and Rit­ux­an met their pri­ma­ry end­point on pro­gres­sion-free sur­vival …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER